Anthony W Tolcher

Anthony W Tolcher

UNVERIFIED PROFILE

Are you Anthony W Tolcher?   Register this Author

Register author
Anthony W Tolcher

Anthony W Tolcher

Publications by authors named "Anthony W Tolcher"

Are you Anthony W Tolcher?   Register this Author

100Publications

5370Reads

35Profile Views

The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-8

New Experimental Therapeutics (NEXT), San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_281103DOI Listing
March 2020

Improving combination cancer therapy: the CombiPlex development platform.

Future Oncol 2018 Jun 24;14(13):1317-1332. Epub 2018 Jan 24.

Jazz Pharmaceuticals, plc, Suite 250, 887 Great Northern Way, Vancouver, British Columbia V5T 4T5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0607DOI Listing
June 2018

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors.

Mol Cancer Ther 2018 01;17(1):3-16

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0349DOI Listing
January 2018

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Nov 29;76(5):1025-32. Epub 2015 Sep 29.

Division of Hematology-Oncology, University of California Los Angeles, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA, 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2883-8DOI Listing
November 2015

Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy.

Biomaterials 2015 Aug 15;59:88-101. Epub 2015 May 15.

Department of Biomedical Engineering, University of Texas at San Antonio, San Antonio, TX 78249, United States.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01429612150031
Publisher Site
http://dx.doi.org/10.1016/j.biomaterials.2015.03.039DOI Listing
August 2015

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Invest New Drugs 2014 Aug 7;32(4):653-60. Epub 2014 Mar 7.

University of Colorado School of Medicine and Developmental Therapeutics Program, University of Colorado Cancer Center, Mail Stop 8117, RC1 South, Rm 8123, 12801 E. 17th Avenue, Aurora, CO, 80045, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0071-zDOI Listing
August 2014

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Jul 22;74(1):195-204. Epub 2014 May 22.

Cancer Therapy and Research Center (CTRC), University of Texas (UT) Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2481-1DOI Listing
July 2014

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Clin Cancer Res 2014 May 28;20(9):2445-56. Epub 2014 Feb 28.

Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2403DOI Listing
May 2014

Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.

Drug Metab Dispos 2013 Dec 16;41(12):2104-13. Epub 2013 Sep 16.

Departments of Drug Metabolism and Pharmacokinetics (H.W., H.L., J.S.H., C.E.C.A.H.), Translational Oncology (S.E.G., B.A.), Clinical Pharmacokinetics (N.B.), Oncology Biomarkers (W.C.D., E.E.K.), Exploratory Clinical Development (C.P., M.M.), Safety Assessment (R.E.), Medicinal Chemistry (J.A.F.), and Early Discovery Biochemistry (W.J.F.), Genentech, Inc., South San Francisco, California; South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas (A.W.T.); and Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee (J.R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.053926DOI Listing
December 2013

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2011 Dec 6;68(6):1565-73. Epub 2011 May 6.

University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1639-3DOI Listing
December 2011

The evolution of phase I trials in cancer medicine: a critical review of the last decade.

Chin J Cancer 2011 Dec 4;30(12):815-20. Epub 2011 Nov 4.

Breast Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://www.cjcsysu.cn/abstract.asp?idno=17782
Publisher Site
http://dx.doi.org/10.5732/cjc.011.10133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013329PMC
December 2011

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Cancer Chemother Pharmacol 2011 Apr 3;67(4):751-64. Epub 2010 Jun 3.

START (South Texas Accelerated Research Therapeutics), 4319 Medical Drive, Suite 205, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1372-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064895PMC
April 2011

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

Clin Cancer Res 2010 May 20;16(9):2656-65. Epub 2010 Apr 20.

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0062DOI Listing
May 2010

Stable disease is a valid end point in clinical trials.

Cancer J 2009 Sep-Oct;15(5):374-8

START-South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-200910000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e3181bdbb05DOI Listing
April 2010

Castration-resistant prostate cancer--hormone therapy redux.

J Clin Oncol 2010 Mar 16;28(9):1447-9. Epub 2010 Feb 16.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.25.3781
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.25.3781DOI Listing
March 2010

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Clin Cancer Res 2009 Jun 19;15(11):3866-71. Epub 2009 May 19.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2373DOI Listing
June 2009

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.

Clin Cancer Res 2008 Dec;14(23):7924-9

Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394092PMC
December 2008

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.

Cancer Chemother Pharmacol 2008 Oct 27;62(5):911-9. Epub 2008 Feb 27.

Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite #414, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0672-8DOI Listing
October 2008

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Cancer Chemother Pharmacol 2008 Jun 6;62(1):97-109. Epub 2007 Sep 6.

Department of Oncology, Pfizer Global Research and Development, 50 Pequot Avenue MS6025-A3238, New London, CT 06320, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0579-4
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0579-4DOI Listing
June 2008

The role of mTOR inhibitors for treatment of sarcomas.

Curr Oncol Rep 2007 Jul;9(4):316-22

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-007-0039-7DOI Listing
July 2007

Technology insight: cytotoxic drug immunoconjugates for cancer therapy.

Nat Clin Pract Oncol 2007 Apr;4(4):245-55

Institute for Drug Development, University of Texas Health Science Center, Suite Z418, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncponc0774
Publisher Site
http://dx.doi.org/10.1038/ncponc0774DOI Listing
April 2007

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Clin Cancer Res 2007 Feb;13(4):1238-45

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1539DOI Listing
February 2007

Management of high risk metastatic prostate cancer: the case for novel therapies.

J Urol 2006 Dec;176(6 Pt 2):S76-80; discussion S81-2

Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002253470601462
Publisher Site
http://dx.doi.org/10.1016/j.juro.2006.06.080DOI Listing
December 2006

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.

Clin Cancer Res 2005 Dec;11(24 Pt 1):8728-36

Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1572DOI Listing
December 2005

Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.

Clin Adv Hematol Oncol 2005 Aug;3(8):635-42, 662

University of Texas Health Sciences Center, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
August 2005

Novel apoptosis inducing agents in cancer therapy.

Curr Probl Cancer 2005 Jan-Feb;29(1):8-32

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S014702720400076
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2004.11.001DOI Listing
June 2005

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

Clin Cancer Res 2004 Nov;10(21):7112-20

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1187DOI Listing
November 2004

Development of novel alkylating drugs as anticancer agents.

Curr Opin Investig Drugs 2004 Jun;5(6):587-91

Cancer Therapy and Research Center, The Institute for Drug Development, 14960 Omicron Drive, San Antonio, TX 78245, USA.

View Article

Download full-text PDF

Source
June 2004

Novel therapies for renal cell carcinoma.

Cancer Treat Res 2003 ;116:227-38

Division of Medical Oncology, University of Texas Health Science Center at San Antonio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-0451-1_14DOI Listing
May 2004

Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor.

J Urol 2004 Feb;171(2 Pt 2):S41-3; discussion S44

Director Clinical Research, Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000108100.53239.b7DOI Listing
February 2004

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

Semin Oncol 2003 Oct;30(5 Suppl 16):79-92

Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.08.010DOI Listing
October 2003

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Clin Cancer Res 2003 Jul;9(7):2465-71

Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
July 2003

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.

Breast Cancer Res 2003 27;5(3):154-9. Epub 2003 Mar 27.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://breast-cancer-research.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/bcr597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC165009PMC
June 2003